Grannus BioSciences Ltd, a privately held biotechnology company developing anti-inflammatory products, announced today two separate agreements with Strathclyde University the first involving a clinical stage compound for use in certain dermatologic and cancer applications. Under a second and separate agreement, Grannus will have an option to as many as six small molecules for development as potential anti-inflammatory pharmaceuticals. The company will collaborate with the Strathclyde Institute for Drug Research (SIDR) which discovered the compounds. Financial terms were not disclosed.
